XAGE
Longevity Health Holdings Inc.
Biotechnology
Market Cap$7M
5Y Perf.-99.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
XAGE vs TALK
Revenue, margins, valuation, and 5-year total return — side by side.
TALK
Talkspace, Inc.
Medical - Care Facilities
Market Cap$868M
5Y Perf.+41.9%
XAGE vs TALK — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | XAGE | TALK |
|---|---|---|
| Industry | Biotechnology | Medical - Care Facilities |
| Market Cap | $7M | $868M |
| Revenue (TTM) | $1M | $229M |
| Net Income (TTM) | $-6M | $8M |
| Gross Margin | 54.6% | 43.0% |
| Operating Margin | -401.0% | 1.4% |
| Forward P/E | — | 38.2x |
| Total Debt | $639K | $0.00 |
| Cash & Equiv. | $157K | $37M |
XAGE vs TALK — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
XAGE
TALK
| Stock | Sep 21 | May 26 | Return |
|---|---|---|---|
| Longevity Health Ho… (XAGE) | 100 | 0.1 | -99.9% |
| Talkspace, Inc. (TALK) | 100 | 141.9 | +41.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: XAGE vs TALK
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TALK leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Longevity Health Holdings Inc. is the stronger pick specifically for growth and revenue expansion. As sector peers, any of these can serve as alternatives in the same allocation.
XAGE
Longevity Health Holdings Inc.
The Growth Play
XAGE is the clearest fit if your priority is growth exposure.
- Rev growth 139.4%, EPS growth 32.4%
- 139.4% revenue growth vs TALK's 22.0%
Best for: growth exposure
TALK
Talkspace, Inc.
The Income Pick
TALK carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 0.86
- -48.7% 10Y total return vs XAGE's -99.9%
- Lower volatility, beta 0.86, current ratio 6.38x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | XAGE | 139.4% revenue growth vs TALK's 22.0% |
| Quality / Margins | TALK | 3.4% margin vs XAGE's -393.6% |
| Stability / Safety | TALK | Beta 0.86 vs XAGE's 1.86 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | TALK | +70.4% vs XAGE's -92.6% |
| Efficiency (ROA) | TALK | 5.9% ROA vs XAGE's -173.9%, ROIC 3.9% vs -38.0% |
XAGE vs TALK — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLTALKLAGGINGXAGE
XAGELongevity Health Hold…
0leads
TALKTalkspace, Inc.
4leads
6 Total Categories
CATEGORYLEADERvs XAGEMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
TALK3/5
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
TALK7/7
Total Returns1Y, 3Y, 5Y total returns with dividends
TALK6/6
Risk & VolatilityBeta, volatility, and downside exposure
TALK2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
TALK leads this category, winning 3 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
TALK is the larger business by revenue, generating $229M annually — 157.1x XAGE's $1M. TALK is the more profitable business, keeping 3.4% of every revenue dollar as net income compared to XAGE's -3.9%. On growth, XAGE holds the edge at +19.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | XAGELongevity Health … | TALKTalkspace, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $1M | $229M |
| EBITDAEarnings before interest/tax | -$6M | $7M |
| Net IncomeAfter-tax profit | -$6M | $8M |
| Free Cash FlowCash after capex | -$4M | -$2M |
| Gross MarginGross profit ÷ Revenue | +54.6% | +43.0% |
| Operating MarginEBIT ÷ Revenue | -4.0% | +1.4% |
| Net MarginNet income ÷ Revenue | -3.9% | +3.4% |
| FCF MarginFCF ÷ Revenue | -2.6% | -0.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | +19.8% | +29.3% |
| EPS Growth (YoY)Latest quarter vs prior year | -4.9% | — |
TALK leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
Evenly matched — XAGE and TALK each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | XAGELongevity Health … | TALKTalkspace, Inc. |
|---|---|---|
| Market CapShares × price | $7M | $868M |
| Enterprise ValueMkt cap + debt − cash | $7M | $830M |
| Trailing P/EPrice ÷ TTM EPS | -0.64x | 129.50x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 38.20x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 137.77x |
| Price / SalesMarket cap ÷ Revenue | 133.03x | 3.79x |
| Price / BookPrice ÷ Book value/share | — | 7.69x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — XAGE and TALK each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
TALK leads this category, winning 7 of 7 comparable metrics.
Profitability & Efficiency
TALK delivers a 6.9% return on equity — every $100 of shareholder capital generates $7 in annual profit, vs $-103 for XAGE. On the Piotroski fundamental quality scale (0–9), TALK scores 6/9 vs XAGE's 4/9, reflecting solid financial health.
| Metric | XAGELongevity Health … | TALKTalkspace, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -103.5% | +6.9% |
| ROA (TTM)Return on assets | -173.9% | +5.9% |
| ROICReturn on invested capital | -38.0% | +3.9% |
| ROCEReturn on capital employed | -47.5% | +2.7% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 6 |
| Debt / EquityFinancial leverage | — | — |
| Net DebtTotal debt minus cash | $481,854 | -$37M |
| Cash & Equiv.Liquid assets | $157,139 | $37M |
| Total DebtShort + long-term debt | $638,993 | $0 |
| Interest CoverageEBIT ÷ Interest expense | -293.50x | — |
TALK leads this category, winning 7 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
TALK leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TALK five years ago would be worth $5,232 today (with dividends reinvested), compared to $11 for XAGE. Over the past 12 months, TALK leads with a +70.4% total return vs XAGE's -92.6%. The 3-year compound annual growth rate (CAGR) favors TALK at 80.7% vs XAGE's -89.8% — a key indicator of consistent wealth creation.
| Metric | XAGELongevity Health … | TALKTalkspace, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +6.4% | +47.6% |
| 1-Year ReturnPast 12 months | -92.6% | +70.4% |
| 3-Year ReturnCumulative with dividends | -99.9% | +490.0% |
| 5-Year ReturnCumulative with dividends | -99.9% | -47.7% |
| 10-Year ReturnCumulative with dividends | -99.9% | -48.7% |
| CAGR (3Y)Annualised 3-year return | -89.8% | +80.7% |
TALK leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
TALK leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
TALK is the less volatile stock with a 0.86 beta — it tends to amplify market swings less than XAGE's 1.86 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TALK currently trades 99.6% from its 52-week high vs XAGE's 3.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | XAGELongevity Health … | TALKTalkspace, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.86x | 0.86x |
| 52-Week HighHighest price in past year | $8.27 | $5.20 |
| 52-Week LowLowest price in past year | $0.23 | $2.22 |
| % of 52W HighCurrent price vs 52-week peak | +3.9% | +99.6% |
| RSI (14)Momentum oscillator 0–100 | 48.5 | 62.7 |
| Avg Volume (50D)Average daily shares traded | 1K | 4.5M |
TALK leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | XAGELongevity Health … | TALKTalkspace, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold |
| Price TargetConsensus 12-month target | — | $5.25 |
| # AnalystsCovering analysts | — | 10 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +2.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
TALK leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 1 category is tied.
Best OverallTalkspace, Inc. (TALK)Leads 4 of 6 categories
Loading custom metrics...
XAGE vs TALK: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is XAGE or TALK a better buy right now?
Talkspace, Inc.
(TALK) offers the better valuation at 129. 5x trailing P/E (38. 2x forward), making it the more compelling value choice. Analysts rate Talkspace, Inc. (TALK) a "Hold" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — XAGE or TALK?
Over the past 5 years, Talkspace, Inc.
(TALK) delivered a total return of -47. 7%, compared to -99. 9% for Longevity Health Holdings Inc. (XAGE). Over 10 years, the gap is even starker: TALK returned -48. 7% versus XAGE's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — XAGE or TALK?
By beta (market sensitivity over 5 years), Talkspace, Inc.
(TALK) is the lower-risk stock at 0. 86β versus Longevity Health Holdings Inc. 's 1. 86β — meaning XAGE is approximately 116% more volatile than TALK relative to the S&P 500.
04Which has better profit margins — XAGE or TALK?
Talkspace, Inc.
(TALK) is the more profitable company, earning 3. 4% net margin versus -206. 1% for Longevity Health Holdings Inc. — meaning it keeps 3. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TALK leads at 1. 4% versus -99. 3% for XAGE. At the gross margin level — before operating expenses — XAGE leads at 87. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — XAGE or TALK?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is XAGE or TALK better for a retirement portfolio?
For long-horizon retirement investors, Talkspace, Inc.
(TALK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 86)). Longevity Health Holdings Inc. (XAGE) carries a higher beta of 1. 86 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TALK: -48. 7%, XAGE: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between XAGE and TALK?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: XAGE is a small-cap quality compounder stock; TALK is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(XAGE: 1975.5% · TALK: 29.3%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.